Tango Therapeutics Inc. Company Profile
NASDAQ: TNGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 22.84 +1.20%
Tango Therapeutics at a glance
Tango Therapeutics Inc. (NASDAQ: TNGX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Boston, MA. Tango Therapeutics is led by Dr. Malte Peters M.D. and employs about 137 people. The company's shares have traded publicly since 2020.
At a market capitalization of $3.81 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001819133, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Tango Therapeutics do?
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Tango Therapeutics Inc.
- Ticker
- NASDAQ: TNGX
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Malte Peters M.D.
- Employees
- 137
- Headquarters
- 201 Brookline Avenue, Boston, MA, United States
- Phone
- 857 320 4900
- Website
- tangotx.com
- IPO year
- 2020
- Market cap
- $3.81B
- SEC CIK
- 0001819133
- Latest annual report
- 10-K · Mar 5, 2026
Companies similar to Tango Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited ADR | 11.01 | -0.99% | $3.74B | vs TNGX |
| ABCLAbCellera Biologics Inc. | 12.02 | -6.31% | $3.90B | vs TNGX |
| LEGNLegend Biotech Corporation ADR | 18.71 | -2.14% | $3.64B | vs TNGX |
| OGNOrganon & Co. | 13.75 | -0.29% | $3.61B | vs TNGX |
| VKTXViking Therapeutics Inc. | 27.73 | -2.84% | $3.53B | vs TNGX |
| XENEXenon Pharmaceuticals Inc. | 36.16 | -0.69% | $3.50B | vs TNGX |
| IDYAIDEAYA Biosciences Inc. | 36.06 | -0.55% | $3.48B | vs TNGX |
| PBLSParabilis Medicines Inc. | 28.09 | -2.53% | $3.47B | vs TNGX |